US Edition
Published • loading... • Updated
AdvanCell Appoints Experienced Biotech and Pharma Leader, Andrew Kay, as Chair of the Board of Directors
Summary by Benzinga
2 Articles
2 Articles
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Andrew Kay as Director and Chair-elect of its Board of Directors, succeeding Bill Ferris AC. Mr. Kay brings extensive…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
